Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.

PloS one - 1 Jan 2017

Oh Jaeseong, Lee SeungHwan, Lee Howard, Cho Joo-Youn, Yoon Seo Hyun, Jang In-Jin, Yu Kyung-Sang, Lim Kyoung Soo

Abstract excerpt

BACKGROUND: Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyses various exogenous and endogenous compounds including oseltamivir, a prodrug used to treat influenza. A novel CES1 c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an in silico analysis. This study evaluated the effect of the c.662A>G SNP on the pharmacokinetics (PK) of oseltamivir in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxylic Ester Hydrolases

Share to Influenza, Human

Share to Oseltamivir

Share to Pharmacogenetics

Share to Tandem Mass Spectrometry

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28437488
DOI: 10.1371/journal.pone.0176320
PMCID: PMC5402961

Genes

CES1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.PMID 28437488Read ↗

The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.Semantic proximity Read ↗

Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.Semantic proximity Read ↗

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Semantic proximity Read ↗

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.Semantic proximity Read ↗

Pharmacogenomic assessment of carboxylesterases 1 and 2.Semantic proximity Read ↗

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir DispositionSemantic proximity Read ↗

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.Semantic proximity Read ↗

Clinical implications of genetic variation in carboxylesterase drug metabolism.Semantic proximity Read ↗

Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability.Semantic proximity Read ↗

Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations.Semantic proximity Read ↗

Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.